Anti-Rel B Antibody [17.3] (A278721)

Anti-Rel B Antibody [17.3]

Mouse monoclonal [17.3] antibody to Rel B.

This antibody recognises the transcription factor RelB, also known as I-Rel. RelB is encoded by the v-rel avian reticuloendotheliosis viral oncogene homolog B gene and is a critical component of the NF-kappa-B pathway.Upon cleavage of the NF-kappa-B p105 and p100 subunits into the NF-kappa-B p50 and p52 subunits, RelB forms RelB-p50 and RelB-p52 heterodimers. These dimers act as activators of transcription by binding to kappaB sites present on DNA. RelB-p50 and RelB-p52 binding induces the expression of genes mediating immune responses, inflammation and apoptosis. Misregulation of the NF-kappa-B pathway has been implicated in a variety of disease states including autoimmunity and cancer. As the NF-kappa-B pathway has been demonstrated to be constitutively active in a large group of tumors, developing NF-kappa-B inhibitors has emerged as a new cancer therapy approach (Chaturverdi et al. 2011 and Baud and Karin et al. 2009).

WB, IHC-P, IP, IF, ICC

ICC: 1 µg/ml, IF: 1 µg/ml, IHC-P: 1:10 - 1:50, WB: 1 - 2 µg/ml

Human, Rhesus Monkey, Mouse

Recombinant protein derived from C-terminus of human RelB protein.

Mouse

Monoclonal

17.3

IgG1

500 µg/ml

Approximately 63 kDa in THP-1 cell lysate, Daudi cell lysate, and Raji cell lysate

Liquid

Supplied in Phosphate Buffered Saline with 0.1% Sodium Azide.

Shipped at ambient temperature. Upon delivery aliquot and store at -20°C. When thawed, aliquot the sample as needed. Short term (up to 4 weeks): store at 4°C. Long term: store at -20°C. Avoid freeze / thaw cycles. Storage in frost free freezers is not recommended.

Mouse anti-RelB antibody, clone 17.3 recognizes the transcription factor RelB, also known as I-Rel. RelB is encoded by the v-rel avian reticuloendotheliosis viral oncogene homolog B gene and is a critical component of the NF-kappa-B pathway.Upon cleavage of the NF-kappa-B p105 and p100 subunits into the NF-kappa-B p50 and p52 subunits, RelB forms RelB-p50 and RelB-p52 heterodimers. These dimers act as activators of transcription by binding to kappaB sites present on DNA (Oeckinghaus and Ghosh 2009). RelB-p50 and RelB-p52 binding induces the expression of genes mediating immune responses, inflammation and apoptosis (Jing and Lee 2014).Misregulation of the NF-kappa-B pathway has been implicated in a variety of disease states including autoimmunity and cancer. As the NF-kappa-B pathway has been demonstrated to be constitutively active in a large group of tumors, developing NF-kappa-B inhibitors has emerged as a new cancer therapy approach (Chaturverdi et al. 2011 and Baud and Karin et al. 2009).

I-Rel, Transcription factor RelB